Nine seats now constitute the Immunic, Inc. (IMUX) board of directors, reduced from ten, after Dr. Duane Nash resigned his directorship effective September 10, 2026. Chief Executive Officer Erik Lundgren signed the SEC 8-K disclosing the governance change on September 11.
The filing's Item 5.02 states Nash's exit was not the result of any disagreement with the company on any matter relating to its operations, policies, or practices. The board voted by resolution to absorb the vacancy rather than replace it. No incoming director or search process was announced alongside the disclosure.
The board and the company expressed gratitude for Nash's service, dedication, and contributions, per the filing.
Immunic is a Delaware corporation headquartered at 1200 Avenue of the Americas, Suite 200, in New York. Its common stock, par value $0.0001 per share, trades on the Nasdaq Stock Market under IMUX. Lundgren signed the report as CEO on September 11, 2026, one day after the reported event date.